Current Setup & Catalysts
Current Setup & Catalysts
The stock is trading at ¥19.64 — exactly 73% below the August 2025 high of ¥73.62 — three days before the May 14, 2026 Q1 2026 release that the market has now spent six weeks repricing in light of the March 11 founder-affiliated US$120M convertible and the FY2025 turn-print. The recent setup is mixed: the operational story actually inflected (revenue +26.7%, first full-year non-GAAP profit ever, Q4 GAAP net income positive), but the tape has wiped the entire 2025 rally and the next four months carry two binary, hard-dated events — the Q1 print and the 618 festival read — back-to-back. The single live debate is whether the FY2025 P&L recovery converts into operating cash flow once the discount-and-dilution noise (Q4 S&M ratio 64.8%, founder convert, ¥372M related-party purchases) is reframed by clean Q1 numbers. The forward calendar is dense and largely visible: between now and August the market gets Q1 prints, the 618 GMV briefs, NDRC certificate news, and the first quarter that proves whether the December 2025 death cross was a regime change or a noise spike.
1. Current Setup in One Page
Recent Setup Rating: Mixed
Hard-Dated Events Next 6 Months
High-Impact Catalysts
Days to Next Hard Date
Current Price (¥)
Drawdown From 2025 High
Setup Pillars Live
Open Watchpoints
Days Until Q1 Print
The single highest-impact near-term event is the May 14, 2026 Q1 2026 release. Three bear-case-defusing watchpoints: (i) revenue at or above the mid-point of management's ¥959M–¥1.08B guide (+15% to +30% YoY); (ii) Q1 S&M as % of revenue below 65% (the FY2025 line, with Q4 having already shown 64.8%); (iii) operating cash flow on a trailing-four-quarter basis less negative than the FY2025 -¥95M baseline. Three of three would materially challenge the 0.25× EV/Sales discount; one of three would leave it intact.
2. What Changed in the Last 3-6 Months
Recent narrative arc. Six months ago the debate was whether YSG would ever turn — the operating loss had compressed from ¥825M to ¥186M but the market was unwilling to pay for it without a clean cash-conversion print. Today the debate has shifted: the turn is partly real (FY non-GAAP NI positive, skincare mix past 50%) but the same release revealed Q4 S&M intensity worsened to 64.8%, and the founder responded with a discount-priced convertible co-investment instead of pure buybacks. The unresolved question is the same as six months ago — does FY2025 operating-line recovery convert into cash by Q1/Q2 2026 — but the cost of being wrong is now higher because the convertible adds a dilution event on top of the operational one.
3. What the Market Is Watching Now
The two debates that actually matter — S&M ratio and operating cash flow — are both first-tested by the Q1 print on Thursday. Everything downstream (618 read, second-tranche close, FY2026 estimate revisions) depends on which side of those two debates the May 14 release sits. The convertible terms, while priced into the tape, are not yet visible to public shareholders in their final closing form — the first tranche had not closed as of the April 29, 2026 20-F filing.
4. Ranked Catalyst Timeline
5. Impact Matrix
6. Next 90 Days
The next 90 days are the densest catalyst window of the next 12 months. Q1 2026 earnings (3 days), 618 festival (5 weeks), and a Second Note tranche close (deal-dependent) all land before mid-August. By contrast, Q3 2026 results and Double 11 2026 are 6 months out, FY2026 OCF resolution is 10 months out, and the holder put on the convertible is 3 years out.
7. What Would Change the View
Three observable signals would reset this debate over the next six months. First, the Q1 2026 S&M ratio: a quarter under 62% — on revenue at or above the mid-point of the guide — would suggest the FY2025 P&L recovery was operating-leverage, not goodwill-comp arithmetic, and would force consensus to re-underwrite the 0.25× EV/Sales discount. Second, the NDRC foreign-debt certificate timing: certificate received plus Second Note closed at original terms locks in five-year tenor and removes the refinancing tail risk that currently sits inside an otherwise clean balance sheet. Third, a Tmall or JD top-10 skincare ranking during 618 (Syntun publishes the brief mid-June) — for the first time since the Eve Lom acquisition — would invalidate the bear case's structural channel-asymmetry argument and ratify the skincare-mix transformation as a real moat, not just a financial-engineering line. Conversely, an S&M ratio above 67% in Q1, combined with another negative-OCF print and zero NDRC progress by August, would confirm the operating treadmill thesis and put the ¥16.99 52-week-low support back in play. The next 14 weeks decide which side of that asymmetry the equity sits on for the back half of 2026.
All figures presented in Renminbi (¥, CNY) for company financials and ¥-equivalent ADS prices. ADS-listed quantities reported in their original currency where conventional (convertible US$120M, conversion price US$4.63/ADS, warrant strike US$10/ADS, US$30M buyback authorization). The companion catalysts-claude-USD.md file translates RMB amounts to USD at the relevant period-end rate.